Detection of proteins from circulating neoplastic cells
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 6, 2011
Grant Date -
Apr 16, 2009
app pub date -
Apr 18, 2007
filing date -
Apr 18, 2006
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The protein EGFR, ERCC1, RRM1, thymidylate synthase, or beta-tubulin from cancer cells is detected in a blood sample by enriching the cancer cells from the blood sample followed by performing on the enriched cancer cells an immunoassay capable of detecting the proteins mentioned above. Cancer patients overexpressing EGFR are treated with an anti-EGFR agent, for example cetuximab, panitumumab, erlotinib or gefitinib.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully